|
|
Press Releases [2009]
MILLIPORE SPONSORS THREE ACADEMIC MEMBERSHIPS FOR THE METAMINER STEM CELL PROJECT
St. Joseph, MI. December 8th, 2009 – GeneGo, Inc., the leading systems biology tools
company, announced today that Millipore Corporation has sponsored academic groups from
University of Queensland, Sheffield and USC to become members of the collaborative
MetaMiner (Stem Cells) project run by GeneGo. MetaMiner is a partnership program for the
reconstruction of stem cell pathways and their application in analysis of experimental data as
well as knowledge mining. Currently, there are seven Members—stem cell experts from top
pharmaceutical companies, the University of Glasgow and Chicago Children’s Hospital—who
direct the development.
“GeneGo is a well-known innovator in the field of pathway analysis and we were always
impressed with the accuracy of their pathways and the quality of experimental data behind the
interactions,” said Siamak Baharloo, Director of e-Business at Millipore.
“In addition to Millipore’s own dedicated team of stem cell scientists, the company has
sponsored stem cell research programs around the world,” said Ruben Flores-Saaib, Sr.
Manager of Scientific Collaborations at Millipore. “Therefore, we decided to support
GeneGo’s effort in stem cells biology, an incredibly important and fast moving research field
through sponsorships to its MetaMiner Stem Cell project.”
The laboratories at the University of Queensland, Sheffield, and USC are conducting leadingedge
research in the field of stem cell biology, and Millipore’s sponsorship allows them to take
part in a scientific initiative to develop biological pathways specific to their areas of interest.
“In our group we study human embryonal carcinoma, and have begun to derive human
induced pluripotent stem cells,” said Martin Pera, Professor and Founding Director, The Eli
and Edythe Broad Center for Regenerative Medicine and Stem Cell Research at USC. “What
we hope to get out of our collaboration with GeneGo is high quality manually curated multi
step pathway maps that encompass all the knowledge in the literature in one place with easy to
use interface tools for knowledge mining and data analysis.”
“We are working on cell and tissue replacement therapies, which hold great promise for the
future treatment of human disease and injury”, said. Professor Peter Andrews of the
Department of Biomedical Science, University of Sheffield. “This will depend upon a
thorough understanding of the biological processes that control the pluripotency, self-renewal
and differentiation capacities of stem cells and their progeny and we hope to get help from our
collaboration with GeneGo to develop pathway maps covering processes to address these
issues we face currently.”
“Millipore is our long-term partner in pathway biology, and we are pleased that they see the
value in this MetaMiner project and have sponsored membership of some of the world leading
stem cell scientists” said Julie Bryant, GeneGo’s VP of Business development. “MetaMiner is a cutting edge system and their expertise will be very useful in the development of high quality pathway content.”
GENEGO LAUNCHES NEW SEARCH PRODUCT-EUREKA! AVAILABLE ON YOUR IPHONE
St. Joseph, MI. November 16th, 2009 – GeneGo, Inc., the leading systems biology tools company, announced today the release of a stand alone search product, Eureka! It provides a simple one-button one-window access to GeneGo’s manually curated databases. Users can query the database with gene, protein, compound, drug names, diseases, and processes, pathological or toxic categories in a free text format. The results, ranked based on relevance, will present all categories of information and data from the database and links to external databases including third party vendors such as Sigma Aldrich. Eureka! is readily available and can be accessed from work, home, even on your iPhone. So users can get the answers they need at any time.
GeneGo will also provide FREE copies of Eureka! to anyone who recommends it to two people that purchase it.
“Eureka! is our entry-level product intended for the “mass market”, which is extremely easy to use, yet supported by the wealth of knowledge we have accumulated in our databases over 10 years”, said Julie Bryant, GeneGo’s VP of Business Development. “We already have over 75 orders for Eureka!, mainly from bench scientists and managers who want to find high quality information quickly without having to learn how to use software.”
GENEGO LAUNCHES NEW WEB SITE WITH FREE PATHWAYS FOR THE BIOLOGY AND CHEMISTRY COMMUNITY
St. Joseph, MI. October 28th, 2009 – GeneGo, Inc., the leading systems biology tools company, announced today that they will be launching a new web site with FREE high quality pathway content. On www.genego.com, anyone can now search for genes, proteins, compounds, processes and diseases and access high quality manually curated pathway maps for human, mouse and rat signaling and metabolism. Every step on the pathways is supported by high quality “small experiment” evidence. The web site includes 37 Cystic Fibrosis specific disease maps, the result of a collaborative development project with Cystic Fibrosis Foundation (CFF).
GeneGo’s new web site also features a new community career section http://www.genego.com/careers.php that anyone can advertise open positions at their companies or institutions. Furthermore, the web site also includes sections with the latest publications using GeneGo technology; it can be searched and there is also product information, events and training sessions on line and at many locations throughout the world.
“With the number of our academic users growing rapidly and GeneGo working with companies to set industry standards, we wanted to ‘give back’ to the life science community that has been loyal to GeneGo for years,” said Julie Bryant, GeneGo’s VP of Business development. ”For the first time, we are now providing free pathway maps that have been expensive to build and a section to help people find jobs in these tough times. We plan to add more ‘community services’ in the next 12 months.”
NIH LIBRARY MAKES METACORE ACCESSIBLE SITE WIDE
St. Joseph, MI. Sept 29th, 2009 – GeneGo, Inc., the leading systems biology tools company, announced today that the NIH Library at Bethesda has licensed MetaCore for NIH staff. MetaCore is an easy to use pathway analysis and data mining tool that provides users with fast easy access to up to date pertinent systems biology related information. Researchers can run simple searches as well as very specific Boolean queries and have answers in seconds or minutes rather than weeks and months using traditional methods. MetaCore also has unique tools for enrichment and interactome analysis of experimental data from gene expression, proteomic, and micro RNA to assay data as well as biomarker studies. Medha Bhagwat, Biomedical Informationist at the NIH Library, is the contact person for information about MetaCore access.
“Many NIH departments have been customers of GeneGo for years, and it is nice to provide broader access to NIH researchers through the library,” said Julie Bryant, GeneGo’s VP of Business development. “Libraries provide a central location for researchers, bench scientists, oncologists, neurologists, bioinformaticians, and core labs to go for systems biology and pathway analysis tools. We will continue to work with the NIH to provide high quality support and training.”
Nothing in this press release constitutes or should be inferred to be an endorsement or recommendation of any product, service, or enterprise by the National Institutes of Health, any other agency of the United States Government, or any employee of the United States Government.
GENEGO LICENSES METACORE TO PROTEOSTASIS THERAPEUTICS
St. Joseph, MI. September 8th, 2009 – GeneGo, Inc., the leading systems biology tools company, announced today that Proteostasis Therapeutics has licensed its data mining and analysis platform, MetaCore. Proteostasis Therapeutics is the first company dedicated to the discovery of novel small molecule therapeutics based upon understanding the body’s Proteostasis Network. The Proteostasis Network maintains the body’s natural balance of proteins to protect us from numerous diseases. Deficiencies of the Proteostasis Network can lead to a wide spectrum of diseases, such as emphysema, type II diabetes, Alzheimer’s Disease and Huntington’s Disease. GeneGo’s MetaCore is developing pathway reconstruction maps for a number of disease categories, including neurodegenerative disorders. Disease-specific pathway maps and models can be used as analytical tools to help advance our understanding of the diseases, their mechanisms and processes to help find cures faster.
“We are very pleased to add Proteostasis as a new customer as we work towards delivering our unique disease specific platforms,” said Julie Bryant, GeneGo’s VP of Business development. “Understanding and capturing disease pathways is one of our top development priorities, and we are glad to see it appreciated by drug discovery companies.”
“Proteostasis Therapeutics is building a proprietary platform to rapidly translate the emerging knowledge of how the Proteostasis Network functions to discover novel small molecules, and GeneGo’s Metacore integrated software suite is a valuable tool in these efforts,” said Hui Ge, Ph.D., Head of Systems Biology at Proteostasis Therapeutics. “We are pleased with GeneGo’s comprehensive curated database of protein interactions, which enables us to rapidly use this information in our Proteostasis Network characterization efforts.”
GENEGO KICKS OFF THE METAMINER STEM CELL PROJECT WITH INDUSTRY AND ACADEMICS
St. Joseph, MI. September 1st, 2009 – GeneGo, Inc., the leading systems biology tools company, announced today that it launched a collaborative development project on systems biology of stem cells with global pharmaceutical companies and leading academic centers as members. The 24-month project aims to create a comprehensive “knowledge base” on development and biology of different types of stem cells. The knowledge base will be supported by GeneGo’s MetaDiscovery tools and applied in experimental research on stem cells and human diseases.
“We are really excited about this project,” said Yuri Nikolsky, CEO of GeneGo. “Although one of the hottest areas of life science, no systematic effort was done on methodical annotation of current experimental knowledge on stem cells, and we intend to fill this gap. Understanding the biology of embryonic adult and neoplastic stem cells is key in both drug discovery and fundamental research in many fields from embryology and ontogenesis to cancer and diabetes.”
“We are very glad to be able to attract an excellent team of members for the cause,” said Julie Bryant, GeneGo’s VP of Business Development. “An industry-academia consortium model fits well with our development objectives in such a complex and controversial field. We believe that the members will see a strong positive return on their investment within several months from the project’s launch.”
GENEGO AWARDED NIH GRANT TO DEVELOP PHARMACOGENOMICS SOFTWARE SUITE
St. Joseph, MI. July 28th, 2009 – GeneGo, Inc., the leading systems biology company, today announced that it has been awarded a grant to develop an integrated systems pharmacology platform for pharmacogenomic research. The SBIR grant, funded through the innovations in biomedical computational science and technology initiative, will be used to develop a database and systems biology tool-set specifically designed for the study of mutations and sequence heterogeneity in human genes and their controlling regions, as well as the biological consequences of sequence variations on disease susceptibility and drug response.
“Genome-wide association studies and next-generation resequencing projects are already generating vast amounts of data on genetic factors contributing to disease susceptibility and variability in the pharmacological and toxicological effects of drugs,” said Richard Brennan, Director of Toxicology at GeneGo and PI on the grant. “What is lacking are powerful tools for researchers to be able to link these sequence variations to the specific mechanisms and biological pathways driving idiosyncratic outcomes. The product will smooth the progress of personalized medicine by facilitating the application of personal genetic profiling to identify optimal therapeutic strategies.”
“Receiving such a prestigious grant award is another example of the cutting edge research at GeneGo that sets us apart from other companies,” said Julie Bryant, GeneGo’s VP of Business Development. “It allows us to develop novel tools and databases to help our customers mine important content from the literature, analyze their data and test their hypotheses.”
GENEGO DONATES PROPRIETARY CYTOKINE PATHWAY MAPS TO ISICR
St. Joseph, MI. July 21st, 2009 – GeneGo, Inc., the leading systems biology tools company, announced today that they have recently donated 41 canonical pathway maps to the International Society for Interferon and Cytokine Research (www.isicr.org). These maps are constructed from manually curated, experimentally validated biological and chemical pathway interactions. Each map describes multi-step signaling covering the full spectrum of cellular signaling from ligand-receptor interaction through enzymes and scaffold proteins to transcription factors. The donated maps describe the role of interferons and cytokines in the immune response, development (via a variety of growth hormones), cell cycle, apoptosis, survival, cell adhesion and chemotaxis. In addition to creating canonical pathway maps GeneGo’s software analysis tools enable functions such as determining the biological enrichment and representative networks for a gene (or list of genes), associated metabolism and diseases, and therapeutic drugs complete with supportive links to the public domain literature. Additional tools include full interactome analysis and chemical analysis tools to predict metabolites and activity as well as target and related functions.
“The ISICR is very grateful for receiving permission from GeneGo to include these maps in the ISICR slide repository. This repository, available to ISICR members, currently has over 500 slides that members can use for seminars, courses, lectures, etc. The addition of the GeneGo pathways will certainly provide ISICR members with an exceptionally valuable educational tool,” said Howard Young, Past President ISICR.
“We are very pleased to help the ISICR with this contribution,” said Julie Bryant, GeneGo’s VP of Business Development. “GeneGo has nearly 800 pathway maps available for data mining and experimental analysis in MetaCore.”
GENEGO AND OMICSOFT ANNOUNCE INTEGRATION
St. Joseph, MI. May 12th, 2009 – GeneGo, Inc., the leading provider of pathway data mining & analysis solutions, and OmicSoft Corporation, the premiere visualization and analysis software for the interpretation of high dimensional data, today announced the integration of the MetaCoreTM pathway analysis platform with Array Studio.
“Array Studio is a powerful analysis platform and we have mutual customers that this integration will benefit,” said Julie Bryant, VP of Business Development at GeneGo. “One of the key parts of this integration will be for users of Array Studio to easily access GeneGo’s wealth of canonical pathway maps, in order to enhance their data analysis and hypothesis testing workflow.”
“MetaCore integration with Array Studio will have an immediate impact for some of our mutual clients, taking the analysis results generated by Array Studio and moving it to the next level with GeneGo's pathway analysis tools.” said Jack Liu, President at OmicSoft. “GeneGo’s flexibility and collaborative thinking has made this a smooth integration, and we look forward to working more with them in the future.”
CARDIFF UNIVERSITY BECOMES A GENEGO CENTER OF EXCELLENCE
St. Joseph, Michigan, April 22nd, 2009 – GeneGo, Inc., a leading provider of software and databases for systems biology and pathway analysis, today announced that the University of Cardiff has become a certified GeneGo Center of Excellence. Cardiff University researchers will have access to GeneGo’s MetaCore, training and advanced support. They will be able to leverage their partner relationship with GeneGo to provide a pathway analysis environment for all the university’s researchers.
“We will be using MetaCore to support a range of researchers across Cardiff University who are using our transcriptomics core facility, including major programs in cancer research, infection and immunity, and neuropsychiatric disease,” said Professor David Kipling, Director of Operations of Central Biotechnology Services.
“We are pleased to add our first GeneGo Center of Excellence in Wales,” said Julie Bryant, Vice President of Business Development at GeneGo. “We look forward to working with David’s group and watching advances they make and publications using MetaCore.”
CHILDREN’S MEMORIAL RESEARCH CENTER, CHICAGO BECOMES A MEMBER OF GENEGO’S METAMINER STEM CELL PARTNERSHIP PROGRAM
St. Joseph, MI. April 14th, 2009 – GeneGo, Inc., the leading systems biology tools company, announced today that Professor Marcelo Bento Soares of Children’s Memorial Research Center has joined the MetaMiner Stem Cell Partnership Program. The goal of the program is to develop a series of blueprint pathway maps for adult, embryonic, fetal, fibroblasts, hematopoietic, mesenchymal, multipotent, neoplastic, pluripotent and totipotent stem cells.
“We feel that it is important to support such an initiative as there is a lot of stem cell information in the literature but no one has brought it all together in a set of comprehensive pathway maps,” said Professor Marcelo Bento Soares, Director, Cancer Biology and Epigenomics Program. “This initiative will allow researchers to have more of a global perspective and allows newcomers to the field to get up to speed quickly.”
“We had our kick off meeting last month and it went very well; we have a lot of other companies and academic groups that want to join this important project as this will be the first stem cell pathway platform for researchers to advance science. Stem cell research is attracting a lot of attention at the moment,” said Julie Bryant, GeneGo’s VP of Business Development. “We have a lot of experience in building pathway maps and we plan to have 10 types of stem cell drug centric pathway maps completed in 24 months.”
VAN ANDEL INSTITUTE JOINS THE METAMINER ONCOLOGY PARTNERSHIP
St. Joseph, MI. March 31st, 2009 – GeneGo, Inc., the leading systems biology tools company, announced today that Craig Webb, Ph.D., director of the Program of Translational Medicine at Grand Rapids, Mich.-based Van Andel Institute, has joined the MetaMiner Oncology Partnership Program.
The goal of the program is to develop a proprietary oncology pathway analysis platform built by experts in the field. This includes developing a series of blueprint pathway maps for cancers, collecting public domain experimental data and normalizing, parsing and making it available for use, as well as developing cancer specific ontologies.
“We feel that it is important to support such an initiative. There is an increasing amount of information in the cancer literature but no one has brought it all together in a set of comprehensive pathway maps that can be further explored,” said Webb “This initiative will allow researchers to have more of a global perspective and allows newcomers to the field to get up to speed quickly.”
Van Andel Institute announced in February an alliance and affiliation agreement with the Phoenix-based Translational Genomics Research Institute (TGen), one of the preeminent translational research organizations in the biomedical industry. “Craig does amazing work at VAI, working with late-stage cancer patients to give them hope, and we are pleased to have him on our team,” said Julie Bryant, GeneGo’s VP of Business Development. “We have a lot of experience in cancer and have received millions of dollars in grants to fund our pioneering research.”
THE NIHR BIOMEDICAL RESEARCH CENTRE FOR MENTAL HEALTH LONDON HAS JOINED THE METAMINER CNS PARTNERSHIP PROGRAM
St. Joseph, MI. March 24th, 2009 – GeneGo, Inc., the leading systems biology tools company, announced today that the NIHR Biomedical Research Centre for Mental Health at the South London and Maudsley NHS Foundation Trust and King’s College London (BRC-MH), has joined the MetaMiner CNS Partnership Program. Professor Simon Lovestone, Centre Director, and Dr Gerome Breen are leading the BRC-MH team for this project. The goal of the program is to develop a proprietary Central Nervous System (CNS) pathway analysis platform built by experts in the field. This includes developing a series of blue print CNS disease pathway maps for Schizophrenia, Alzheimer’s disease and Huntington’s disease, etc as well as collecting experimental data from the public domain, and making it available for analysis.
Professor Lovestone said: “This is an important initiative as it will give researchers a global perspective of CNS pathways and enable those new to the field to get up to speed quickly. Currently there is a huge amount of CNS data available but until now no one has brought it all together in a comprehensive form.”
Dr Breen, BRC-MH Genetics Coordinator, adds “Accurate and comprehensive pathway annotation is necessary for us to discern the biological mechanisms revealed by large scale omics approaches to CNS disorders, such as genomewide association and expression array studies.”
Julie Bryant, GeneGo’s VP of Business Development comments “The BRC-MH at KCL has world class expertise in CNS disorders and we are pleased to have the Centre on our team. We plan to develop excellent and accurately annotated CNS pathway maps, while fully processing experimental data taken from public repositories such as GEO. This will ultimately mean superior CNS pathway annotation and facilitate easier data analysis and exploration for our customers.”
GENEGO ANNOUNCES SYSTEMS TOX RELATIONSHIP WITH ENTELOS
St. Joseph, MI. March 17th, 2009 – GeneGo, Inc., the leading provider of pathway data mining & analysis solutions, today announced a license agreement with Entelos of Foster City, CA, a company specializing in predictive technologies, including toxicogenomics and PhysioLab® virtual human disease models. GeneGo will use Entelos’ DrugMatrix® gene expression data to further develop GeneGo’s Functional Descriptor predictive toxicology models.
“Access to a comprehensive, pharmacologically-diverse and fully annotated compendium of gene expression data is critical to developing high-performance predictive models,” said Richard Brennan, Director of Toxicology at GeneGo. “This is one of the key goals of our MetaTox partnership. DrugMatrix is the largest toxicogenomic database available, and will allow us to apply the lessons we have learned from our participation in the Microarray Quality Control Consortium to expand our collection of biological pathway-based classifiers with toxicity models for a wide variety of adverse drug effects in key target tissues.”
“We are very pleased to be working with GeneGo and participating in their MetaTox projects,” said Alan Roter, VP of Informatics at Entelos. “GeneGo’s unique approach of generating functional descriptors is a great complement to the classifiers and predictive models in DrugMatrix, and we see great benefit to the scientific community using predictive toxicogenomics.”
MILLIPORE LAUNCHES AN INTERACTIVE BIOLOGICAL PATHWAY TOOL USING GENEGO’S MANUALLY CURATED PATHWAY MAPS
St. Joseph, MI. February 17th 2009 – GeneGo, Inc., the leading systems biology tools company, announced today that Millipore has licensed 250 manually curated pathway maps from GeneGo, Inc. for their new Interactive Biological Pathway Tool. Available at www.millipore.com/pathways, the tool links Millipore’s cutting edge antibodies, proteins, and assays as well as relevant bioinformatics content to related biological pathways. These maps have been categorized by diseases and cellular processes to make it easier to find relevant information.
“In many cases, discovering the mechanisms of disease and uncovering new drug targets requires an understanding of not just individual biological events, but key biological pathways,” said Siamak Baharloo, PhD, Director of eBusiness at Millipore. “This tool provides a relevant new interface to assist scientists in planning and executing their research within the context of the biological systems in which they are interested.”
When a researcher accesses a pathway map, they see a detailed description of the pathway and supporting literature references. As the researcher selects protein or gene targets along the pathway, information is dynamically populated into a Target Information Dashboard. The dashboard information includes the gene symbol and aliases; links to bioinformatics content and recent publications; as well as links to appropriate Millipore products.
“We are very pleased to see the Millipore site go live in record time and respect their dedication to high quality products and pathways to showcase them,” said Julie Bryant, VP of Business Development. “We look forward to a long term relationship with Millipore as they make valuable content and tools available to their customer base.”
WASHINGTON UNIVERSITY BECKER LIBRARY MAKES METACORE ACCESSIBLE THROUGHOUT THE UNIVERSITY
St. Joseph, MI. February 10th, 2009 – GeneGo, Inc., the leading systems biology tools
company, announced today that Becker Medical Library at Washington University in St. Louis
has licensed MetaCore. The Becker Medical Library Bioinformatics@Becker program is a
university wide resource which provides bioinformatics support for researchers and students.
MetaCore is an easy to use data mining tool that provides users with fast easy access to up to
date pertinent pathway information. Researchers can run simple searches as well as very
specific Boolean queries and have answers in seconds or minutes rather than weeks and
months using traditional methods. MetaCore can also be used for pathway analysis of all kinds
of experimental data from gene expression, micro RNA to assay data as well as biomarker
studies.
“Becker Medical Library at Washington University in St. Louis is an important customer for
GeneGo as we build up the number of libraries using GeneGo products,” said Julie Bryant,
GeneGo’s VP of Business development. “Libraries are the heart of most academic centers and
an excellent resource for PI’s, researchers and students where systems biology comes together
with all types of experimental data, biologists, chemists and pharmacologists and therapeutic
focuses.”
QUEENSLAND FACILITY FOR ADVANCED BIOINFORMATICS (QFAB) BECOMES A GENEGO CENTER OF EXCELLENCE FOR THE ASIA PACIFIC REGION
St. Joseph, MI. February 2nd, 2009 – GeneGo, Inc., the leading systems biology tools
company, announced today that QFAB has licensed MetaCore and entered a co marketing
agreement with GeneGo for the Asia Pacific region. QFAB will have GeneGo certified
experts on staff to run training classes in the region and support the local research community.
QFAB will make MetaCore pathway tools, software and manually curated databases accessible
to Australian and New Zealand academics as part of its delivery of tailored bioinformatics
solutions to life science researchers in the region.
Jeremy Barker, QFAB’s Chief Executive Officer said, “We are currently using MetaCore for an in-house project and have seen the power that it provides in a systems biology framework.
In partnering with GeneGo we aim to help researchers in our part of the world realize the
benefits that can come from using this software.”
“We are very excited about this relationship as we will work together to open up and support
Australia, New Zealand and beyond,” said Julie Bryant, GeneGo’s VP of Business
development. “We will be jointly supporting a lot of marketing and research activities in the
region as there is a lot of exciting and novel research we would like to be involved in.”
UNIVERSITY OF GLASGOW BECOMES A MEMBER OF GENEGO’S METAMINER STEM CELL PARTNERSHIP PROGRAM
St. Joseph, MI. January 27th, 2009 – GeneGo, Inc., the leading systems biology tools company, announced today that Professor Nicol Keith of the University of Glasgow will join the MetaMiner Stem Cell Partnership Program. The goal of the program is to develop a series of blue print pathway maps for Adult, Embryonic, Fetal, Fibroblasts, Hematopoietic, Mesenchymal, Multipotent, Neoplastic, Pluripotent and Totipotent stem cells.
“We feel that it is important to support such an initiative as there is a lot of stem cell information in the literature but no one has brought it all together in a set of comprehensive pathway maps,” said Nicol Keith, Professor of Molecular Oncology. “This initiative will allow researchers to have more of a global perspective and allows newcomers to the field to get up to speed quickly.”
“Professor Nicol Keith, of the University of Glasgow in Scotland is world renowned for his pioneering work in cellular immortality and we are pleased to have him on our team,” said Julie Bryant, GeneGo’s VP of Business Development. “We have a lot of experience at building pathway maps and we plan to have 10 types of stem cell pathway maps completed in 24 months.”
PACIFIC NORTHWEST NATIONAL LABORATORIES BECOMES A GENEGO CENTER OF EXCELLENCE
St. Joseph, MI. January 20th, 2009 – GeneGo, Inc., the leading systems biology tools company, announced today that the Department of Energy’s Pacific Northwest National Laboratory (PNNL) has become a certified GeneGo Center of Excellence. PNNL researchers will have institution-wide access to GeneGo’s MetaCore data analysis suite, training and advanced support. PNNL advances the science and technology to address complex national challenges in fundamental science as well as energy, environment and national security. MetaCore will be used throughout many research programs both as a central data repository, management and collaboration platform for OMICs data analysis and as an integrative pathway analysis suite.
“PNNL has been a long time GeneGo customer and the user base is continuously growing.” said Julie Bryant, GeneGo’s VP of Business development. “They are taking advantage of our EZ search data mining tools that quickly provides answers to their systems biology and pathway questions.”
GENEGO RENEWS ITS AGREEMENT WITH BAYER SCHERING PHARMA AG FOR ANOTHER THREE YEARS
St. Joseph, Michigan, January 6th, 2009 – GeneGo, Inc., a leading provider of software and high quality manually curated databases for systems biology and pathway analysis, today announced that Bayer Schering Pharma AG has renewed its MetaCore licenses for another three years. Bayer Schering Pharma has programs for cancer, cardiovascular diseases and gynecological therapies and GeneGo has good coverage of these diseases and others. GeneGo is also in the process of building disease specific platforms in cancer and the cardiovascular area that include blue print pathway maps for the disease, processes and mechanisms as well as offering public domain experimental data and disease ontologies.
“Bayer Schering Pharma was one of our first customers and we appreciate their loyalty,” said Julie Bryant, Vice President of Business Development at GeneGo. “MetaCore is widely used in Bayer in multiple departments including bioinformatics, oncology, cardiology and women’s health for data mining and analysis of multiple omics experimental data such as gene expression and proteomics.”
|
